An observational study in Myocardial Infarction (MI), ST-Elevation Myocardial Infarction and STEMI, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in ST Elevation Myocardial Infarction with a site in Austria — 7 open to participants now, 9 under way, none of them phase 3. ST Elevation Myocardial Infarction · Austria.
Among the 23 studies in ST Elevation Myocardial Infarction with a site in Austria, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 21st registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →7 of the 23 studies in ST Elevation Myocardial Infarction with a site in Austria are open now. Recruiting first, the newest first:
Medical University Innsbruck · Sites in Austria
Ages 18–75 · Healthy volunteers
Medical University Innsbruck · Sites in Austria, Germany
Ages 18+
RobotDreams GmbH · Sites in Austria
Ages 18+ · Healthy volunteers
Medical University Innsbruck · Sites in Austria, Germany
Ages 18–85
Medical University Innsbruck · Sites in Austria
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is below the median of 340 across 298 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 161 across the 14 interventional studies, 350 across the 9 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 6 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in ST Elevation Myocardial Infarction with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07780552VASCage GmbHCHIP in Health and Disease | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in ST Elevation Myocardial Infarction with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.
The aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
This study's planned enrollment of 300 is below the median of 340 across 298 observational studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Consecutive adult patients admitted with STEMI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Drug-Coated Balloon
Provisional DCB-based pPCI for a de novo coronary
Also known as: Drug-Eluting Balloon, DCB, DEB
Net adverse clinical events (NACE)
Composite of :Device success, Procedural success, Angiographic success diameter stenosis \<40% by visual estimation and TIMI flow grade ≥2, Target vessel dissection ≥ type C, Bailout stenting
Time frame: From January 2014 to April 2026
Individual NACE components
Time frame: Jenuary 2014 to April 2026
Any Bleeding
Any bleeding classified according to the Bleeding Academic Research Consortium (BARC) criteria.
Time frame: January 2014- April 2026
Target Vessel Failure (TVF)
Composite of cardiovascular death, target vessel myocardial infarction, or target vessel revascularization, according to Academic Research Consortium drug-coated balloon consensus definitions.
Time frame: January 2014-April 2026
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jul 2026, 5 months after the start.
Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 107. This study's planned 5 months is below that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 21 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Medical University of Vienna →